Abstract
Medicare's Hospital Readmissions Reduction Program (HRRP) has been credited with lowering risk-adjusted readmission rates for targeted conditions at general acute care hospitals. However, these reductions appear to be illusory or overstated. This is because a concurrent change in electronic transaction standards allowed hospitals to document a larger number of diagnoses per claim, which had the effect of reducing risk-adjusted patient readmission rates. Prior studies of the HRRP relied upon control groups' having lower baseline readmission rates, which could falsely create the appearance that readmission rates are changing more in the treatment than in the control group. Accounting for the revised standards reduced the decline in risk-adjusted readmission rates for targeted conditions by 48 percent. After further adjusting for differences in pre-HRRP readmission rates across samples, we found that declines for targeted conditions at general acute care hospitals were statistically indistinguishable from declines in two control samples. Either the HRRP had no effect on readmissions, or it led to a systemwide reduction in readmissions that was roughly half as large as prior estimates have suggested.
Original language | English (US) |
---|---|
Pages (from-to) | 36-43 |
Number of pages | 8 |
Journal | Health Affairs |
Volume | 38 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
Funding
All authors acknowledge receiving funding from the Agency for Healthcare Research and Quality (Grant No. U19 HS24072). The authors thank Michael McWilliams for helpful comments. Leemore Dafny reports being a member of the Panel of Health Advisers for the Congressional Budget Office, being an academic affiliate of and providing expert witness support in antitrust matters for Bates White Economic Consulting, being on the board of the Health Care Cost Institute, receiving personal fees and nonfinancial support from the Massachusetts Medical Society, and advising a health care system on strategic alliances. David Grabowski served as a paid consultant to Precision Health Economics, Vivacitas, and CareLinx. He also serves on the Scientific Advisory Committee for NaviHealth. David Cutler serves as a paid consultant (receiving in excess of $5,000.00 per year in the past twelve months) to the Scientific Advisory Board, F-Prime Capital Partners (formerly the Scientific Advisory Board, Fidelity Investments); and Mercer Health and Benefits, LLC.
ASJC Scopus subject areas
- Health Policy